Publikationen in Zusammenarbeit mit Forschern von Hospital General Universitario Gregorio Marañón (19)

2024

  1. A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis

    Cancers, Vol. 16, Núm. 9

  2. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

    Annals of Hematology

  3. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection

    Haematologica, Vol. 109, Núm. 6, pp. 1909-1917

2023

  1. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

    Blood, Vol. 142, Núm. 18, pp. 1518-1528

2022

  1. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

    Blood cancer journal, Vol. 12, Núm. 4, pp. 68

2021

  1. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

    Blood Cancer Journal, Vol. 11, Núm. 5

  2. Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 6, pp. 413-420

  3. The current role of the heavy/light chain assay in the diagnosis, prognosis and monitoring of multiple myeloma: An evidence-based approach

    Diagnostics, Vol. 11, Núm. 11

2016

  1. Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma

    European Journal of Haematology, Vol. 96, Núm. 5, pp. 532-540

  2. Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS

    Bone Marrow Transplantation, Vol. 51, Núm. 7, pp. 961-966

2015

  1. Gammapatías biclonales: ¿un significado clínico diferente?

    Revista Clinica Espanola

2007

  1. Comparison of the MagNA pure LC automated system and the RiboPure-Blood RNA manual method for RNA extraction from multiple myeloma bone marrow samples conserved in an RNA stabilizer

    International Journal of Laboratory Hematology, Vol. 29, Núm. 2, pp. 139-144

2006

  1. Application of self-quenched JH consensus primers for real-time quantitative of PCR of IGH gene to minimal residual disease evaluation in multiple myeloma

    Journal of Molecular Diagnostics, Vol. 8, Núm. 3, pp. 364-370

  2. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients [14]

    Leukemia

2004

  1. The use of fluorescent molecular beacons in real time PCR of IgH gene rearrangements for quantitative evaluation of multiple myeloma

    Clinical and Laboratory Haematology, Vol. 26, Núm. 1, pp. 31-35

2001

  1. Karyotype and prognosis in adult Spanish acute lymphoblastic leukemia [4]

    Haematologica

1985

  1. Six new cases of prolymphocytic leukemia with heterogeneous prognosis. Clinical and immunologic features, light microscopy, and ultrastructural findings

    Cancer, Vol. 55, Núm. 11, pp. 2550-2557

1984

  1. Evolving polycythemia vera and Wegener's granulomatosis

    Annals of Internal Medicine

1979

  1. EPISODIOS INFECCIOSOS EN PACIENTES GRANULOCITOPENICOS CON LEUCEMIA MIELOIDE AGUDA. ANALISIS DE LOS FACTORES PRONOSTICOS EN NOVENTA Y NUEVE CASOS

    Sangre, Vol. 24, Núm. 5 B, pp. 868-877